Axcan Updates on Upcoming Analyst and Investor Events

MONT-SAINT-HILAIRE, QUEBEC (TSX: AXP)(NASDAQ: AXCA) today announced that following the disclosure of the Agreement for Axcan to be acquired by TPG Capital and its affiliates, the Company would like to inform all interested parties that it will no longer be holding its conference call on Friday 30 November, 2007, to discuss Axcan's fourth quarter and fiscal year results.

Axcan was also scheduled to present on Tuesday, December 4, 2007, at the BMO Capital Markets Focus on Healthcare Conference to be held in New York. The Company announced that it will no longer be presenting at this event.

Axcan also announced that its Analyst and Investor event, that was to be held on Thursday, December 6, 2007, in New York, has been cancelled.

For further details on the Agreement for Axcan to be acquired by TPG Capital and its affiliates, please refer to the press release issued by Axcan at 8:40 a.m. Eastern time today.

ABOUT AXCAN PHARMA

Axcan is a leading multinational specialty pharmaceutical company focused on gastroenterology. The Company develops and markets a broad line of prescription products to treat a range of gastrointestinal diseases and disorders such as inflammatory bowel disease, irritable bowel syndrome, cholestatic liver diseases and complications related to pancreatic insufficiency. Axcan's products are marketed by its own specialized sales forces in North America and Europe. Its common shares are listed on the NASDAQ Global Market under the symbol "AXCA" and on the Toronto Stock Exchange under the symbol "AXP".

Contacts: Axcan Pharma Inc. Isabelle Adjahi Senior Director, Investor Relations and Communications 450-467-2600 ext. 2000 www.axcan.com

Axcan Pharma (MM) (NASDAQ:AXCA)
Historical Stock Chart
From Dec 2024 to Jan 2025